Bioleaders Corporation

MOA Life Plus Co. Ltd. operates in the medicine and consumer business in South Korea. Its pipeline includes P53, a targeted anti-cancer drug, and candidates such as BLS-H01 (phase 3 for cervical cancer), BLC-H03 (preclinical vaccine adjuvant), BLS-M07 (completed phase 2b for cervical cancer), and BLS-M22 (completed phase 1 for Duchenne muscular dystrophy). The company also provides health functional food, raw materials, and cosmetics. Formerly Bioleaders Corporation, it changed its name to MOA Life Plus Co. Ltd. in March 2024, and is headquartered in Yongin-Si, South Korea, having been founded in 1999.